Your search returned 6 results.

Sort
Results
1.
Pertuzumab for the treatment of breast cancer: a safety review. [Review] MedStar authors:
  • Swain, Sandra M
PMID:
  • 26982349
Year: 2016
Citation:
  • Expert Opinion on Drug Safety. 15(6):853-63, 2016 Jun
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Journal Article
  • Review
Form of publication:
  • Journal Article
All authors:
  • Gao J, Swain SM
2.
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors:
  • Swain, Sandra M
PMID:
  • 24869931
Year: 2014
Citation:
  • Oncologist. 19(7):693-701, 2014 Jul.
Institution:
  • Washington Cancer Institute
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM
3.
Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. [Review] MedStar authors:
  • Swain, Sandra M
PMID:
  • 23530718
Year: 2013
Citation:
  • Expert Opinion on Biological Therapy. 13(5):779-90, 2013 May.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review
Form of publication:
  • Journal Article
All authors:
  • O'Sullivan CC, Swain SM
4.
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
  • Swain, Sandra M
PMID:
  • 23868905
Year: 2013
Citation:
  • Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
5.
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
  • Asch, Federico M
  • Barac, Ana
  • Cunningham, A
  • Gallagher, Christopher
  • Hofmeyer, Mark
  • Srichai, M B
  • Swain, Sandra M
PMID:
  • 30852761
Year: 2019
Citation:
  • Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
  • MedStar Health
  • MedStar Health Research Institute
  • MedStar Heart & Vascular Institute
  • Washington Cancer Institute
Department:
  • Associate Dean for Research Development
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
6.
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors:
  • Swain, Sandra M
PMID:
  • 34890214
Year: 2022
Citation:
  • Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.
Department:
  • Associate Dean for Research Development
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP
Pages

Powered by Koha